Interpretation of the switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10 in Belgium
Lancet Infect Dis
.
2018 Aug;18(8):831-832.
doi: 10.1016/S1473-3099(18)30410-9.
Epub 2018 Jul 11.
Authors
Patricia Izurieta
1
,
Thomas Breuer
2
Affiliations
1
GlaxoSmithKline, Wavre, Belgium.
2
GlaxoSmithKline, Wavre, Belgium. Electronic address: thomas.breuer@gsk.com.
PMID:
30001856
DOI:
10.1016/S1473-3099(18)30410-9
No abstract available
Publication types
Letter
Comment
MeSH terms
Belgium
Immunization Programs*
Pneumococcal Vaccines
Streptococcus pneumoniae*
Vaccination
Substances
10-valent pneumococcal conjugate vaccine
Pneumococcal Vaccines